Who AstraZeneca buys from and sells to
UK maker of cancer, cardiovascular, respiratory and rare-disease drugs (Tagrisso, Farxiga, Enhertu).
Buys from 2
- Daiichi SankyoDSNKYEnhertu and Datroway, co-commercialised antibody-drug conjugates
- Samsung Biologicscontract biologics manufacturing
Where the chain could break
- Three wholesalers took ~78% of 2025 US sales
- China was 12% of 2025 product sales, exposed to probes and volume-based procurement
Competes with
- MerckMRKKeytruda against Imfinzi in immuno-oncology
- Eli LillyLLYJardiance against Farxiga in SGLT2 drugs
- NovartisNVSoncology and cardiovascular drugs
Mapped by hand from filings and company reporting, as of October 2026. It shows the relationships that matter most, not every contract: most are never disclosed, and agreements change.